Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2006-08-22
2006-08-22
Wehbe, Anne M. (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093600, C435S320100
Reexamination Certificate
active
07094399
ABSTRACT:
The present invention provides methods and compositions for conferring tumor selective cell death on cancer cells expressing specific target precursor messenger RNA molecules (cancer cell selective target pre-mRNAs). The compositions of the invention include conditionally replicative adenoviruses that have been genetically engineered to express one or more pre-trans-splicing molecules (PTMs) designed to interact with one or more cancer cell target pre-mRNA and mediate a trans-splicing reaction resulting in the generation of novel chimeric RNA molecules (chimeric RNA) capable of encoding adenovirus specific protein(s). Adenovirus specific proteins include those proteins complementing an essential activity necessary for replication of a defective adenovirus. The methods and compositions of the invention may be used to target a lytic adenovirus infection to cancer cells thereby providing a method for selective destruction of cancer cells. In addition, the adenoviruses of the invention may be engineered to encode PTMs designed to interact with target pre-mRNAs encoded by infectious agents within a cell, thereby targeting selective destruction of cells infected with such agents.
REFERENCES:
patent: 4980286 (1990-12-01), Morgan et al.
patent: 5354678 (1994-10-01), Lebkowski et al.
patent: 5585362 (1996-12-01), Wilson et al.
patent: 5589377 (1996-12-01), Lebkowski et al.
patent: 5616326 (1997-04-01), Spibey
patent: 5670488 (1997-09-01), Gregory et al.
patent: 5700470 (1997-12-01), Saito et al.
patent: 5731172 (1998-03-01), Saito et al.
patent: 5747072 (1998-05-01), Davidson et al.
patent: 5756283 (1998-05-01), Wilson et al.
patent: 5789390 (1998-08-01), Descamps et al.
patent: 5820868 (1998-10-01), Mittal et al.
patent: 5837484 (1998-11-01), Trempe et al.
patent: 5843742 (1998-12-01), Natsoulis et al.
patent: 5851806 (1998-12-01), Kovesdi et al.
patent: 5858351 (1999-01-01), Podsakoff et al.
patent: 5869037 (1999-02-01), Crystal et al.
patent: 5871982 (1999-02-01), Wilson et al.
patent: 5877011 (1999-03-01), Armentano et al.
patent: 5885808 (1999-03-01), Spooner et al.
patent: 5891690 (1999-04-01), Massie
patent: 5919676 (1999-07-01), Graham et al.
patent: 5922576 (1999-07-01), He et al.
patent: 5928944 (1999-07-01), Seth et al.
patent: 5932210 (1999-08-01), Gregory et al.
patent: 5952221 (1999-09-01), Kurtzman et al.
patent: 5962311 (1999-10-01), Wickham et al.
patent: 5962313 (1999-10-01), Podsakoff et al.
patent: 5998205 (1999-12-01), Hallenbeck et al.
patent: 6013487 (2000-01-01), Mitchell
patent: 6083702 (2000-07-01), Mitchell et al.
patent: 6280978 (2001-08-01), Mitchell et al.
patent: 2002/0115207 (2002-08-01), Mitchell et al.
Somia and Verma, 2000, Nature Reviews: Genetics, 1:91-99.
Heise et al., 1999, Cancer Research, 59: 2623-2628.
Platt, 1998, Nature, 392 supplement: 11-17.
Gage, 1998, Nature, 392 supplement, pp. 18-24.
Fisher, 1997, Neurobiology of Disease, 4: 1-22.
Wada et al., 2000, PNAS, 97: 10954-10959.
Puttaraju et al., 1999, Nature Biotechnology, 17: 246-252.
Rochlitz, 2001, Swiss Med Wkly, 131: 4-9.
Bhaumik et al., 2004, PNAS, 101: 8693-8698.
U.S. Appl. No. 10/693,192, filed Oct. 23, 2003, “Screening method for identification of efficient pre-trans-splicing molecules,” Mitchell et al.
U.S. Appl. No. 10/374,784, filed Feb. 25, 2003, “Trans-splicing mediated imaging of gene expression,” Mitchell et al.
U.S. Appl. No. 10/360,787, filed Jun. 5, 2002, “Spliceosome mediated RNA trans-splicing for correction of factor VIII genetic defects,” Mitchell et al.
U.S. Appl. No. 10/198,447, filed Jul. 17, 2002, “Spliceosome mediated RNA trans-splicing for correction of skin disorders,” Mitchell et al.
U.S. Appl. No. 10/136,723, filed Apr. 30, 2002, “Transgenic animal model for spliceosome-mediated RNA trans-splicing,” Puttaraju et al.
U.S. Appl. No. 10/103,294, filed Mar. 30, 2002, “Spliceosome mediated RNA trans-splicing,” Mitchell et al.
U.S. Appl. No. 10/075,028, filed Mar. 12, 2002, “Method and compositions for use in spliceosome mediated RNA trans-splicing,” Mitchell et al.
U.S. Appl. No. 10/076,248, filed Feb. 12, 2002, “Method and compositions for use in spliceosome mediated RNA trans-splicing,” Mitchell et al.
U.S. Appl. No. 10/941,492, filed Aug. 29, 2001, “Method and compositions for use in spliceosome mediated RNA trans-splicing,” Mitchell et al.
U.S. Appl. No. 09/838,858, filed Apr. 20, 2001, “Method and compositions for use in spliceosome mediated RNA trans-splicing,” Mitchell et al.
U.S. Appl. No. 09/756,097, filed Jan. 8, 2001, “Method and compositions for use in spliceosome mediated RNA trans-splicing,” Mitchell et al.
U.S. Appl. No. 09/756,096, filed Jan. 8, 2001, “Methods and compositions for use on spliceosome mediated RNA trans-splicing,” Mitchell et al.
Bhaumik et al., 2004, “Molecular Imaging of Gene Expression in Living Subjects by Spliceosome-Mediated RNA Trans-Splicing,” Proc. Natl. Acad. Sci. USA, 101:8693-8698.
Tahara et al., 2004, “Trans-Splicing Repair of CD40-Ligand Deficiency Results in Naturally Regulated Correction of a Mouse Model of Hyper-IgM X-Linked Immunodeficiency,” Nature Medicine, 10:835-841.
Chao et al., 2003, “Phenotype correction of Hemophilia A Mice by Spliceosome-Mediated RNA Trans-splicing,” Nature Medicine, 9:1-5.
Liu et al., 2002, “Partial Correction of Endogenous Delta 508 CFTR in Human Cystic Fibrosis Airway Epithelia by Spliceosome-Mediated RNA Trans-Splicing,” Nature Biotechnology, 20:47-52.
Kim et al., 2001,“Role of the Nonsense-Mediated Decay Factor hUpf3 in the Splicing Dependent Exon—Exon Junction Complex,” Science 293:1832-1836.
Kirn et al., 2001, Replication-selective virotherapy for cancer:Biological principles, risk management and future directions, Nat. Med. 7:781-787.
Tian et al., 2001, “Strong RNA Splicing Enhancers Identified by a Modified Method of Cycled Selection Interact with SR Protein,” J. Biological Chemistry 276:33833-33839.
Mansfield et al., 2000, “Repair of CFTR mRNA by spliceosome-mediated RNA trans-splicing,” Gene Therapy 7:1885-1895.
Tacke et al., 1999, “Determinants of SR protein specificity,” Curr. Opin. Cell Biol. 11:358-362.
He et al. 1998, “A Simplified System for Generating Recombinant Adenoviruses,” Proc. Natl. Acad. Sci. USA, 95, 2509-2514.
Lan N et al., 1998, “Ribozyme-mediated Repair of Sickle β-Globin mRNAs in Erythrocyte Precursors” Science 280:1593-1596.
Phylactou LA et al., 1998, “Ribozyme-mediated trans-splicing of a trinucleotide repeat” Nature Genetics 18:378-381.
Staley JP et al., 1998, “Mechanical Devices of the Spliceosome: Motors, Clocks, Springs and Things” Cell 92:315-326.
Bellet et al., 1997, “Malignant transformation of nontrophoblastic cells is associated with the expression of chorionic gonadotropin β genes normally transcribed introphoblastic cells,” Cancer Res. 57:516.
Coolidge et al., 1997, “Functional analysis of the polypyrimidine tract in pre-mRNA splicing,” Nucleic Acids Res. 25:888.
Crouzet et al. 1997, “Recombinational Construction inEscherichia coliof Infectious Adenoviral Genomes,” Proc. Natl. Acad. Sci. USA, 94, 1414-1419.
Good et al., 1997, “Expression of Small, Therapeutic RNAs in Human Cell Nuclei,” Gene Ther. 4:45-54.
Malek O et al., 1997, “Evolution of trans-splicing plant mitochondrial introns in pre-Permian times” Proc. Nat'l Acad. Sci. USA 94:553-558.
Chartier, et al. 1996, “Efficient Generation of REcombinant Adenovirus Vectors by Homologous Recombination inEscherichia coli,” J Virol. 70, 4805-4810.
Hoon et al., 1996, “Detection of metastatic breast cancer by β-hCG polymerase chain reaction,” Int J. Cancer 69:369.
Jones JT et al., 1996, “Tagging ribozyme reaction sites to follow trans-splicing in m
Arent & Fox PLLC
Hama Joanne
Intronn, Inc.
Wehbe Anne M.
LandOfFree
Use of spliceosome mediated RNA trans-splicing to confer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of spliceosome mediated RNA trans-splicing to confer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of spliceosome mediated RNA trans-splicing to confer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3629368